Overview

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy. To investigate the safety and tolerability of Tripterygium wilfordii plus steroid
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Zhi-Hong Liu, M.D.
Treatments:
Prednisone
Tacrolimus
Criteria
Inclusion Criteria:

1. Biopsy-proven idiopathic membranous nephropathy

2. Nephrotic syndrome with proteinuria ( > 3.5 g/day) and serum albumin < 30 g/dl

3. Age 18-65 years with informed consent

Exclusion Criteria:

1. Patient with elevated serum creatinine concentration

2. Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil,
levamisole, methotrexate, or nitrogen mustard in the last 90 days

3. Active/serious infection

4. Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

5. Patient who is diabetic

6. Patient is allergic or intolerant to macrolide antibiotics or tacrolimus